Lenvatinib/lenvatinib (Lenvima) efficacy and possible side effects

Lenvatinib/Lenvatinib is a multi-target tyrosine kinase inhibitor (TKI) developed by Eisai of Japan and used to treat a variety of advanced solid tumors. As a targeted anti-cancer drug, lenvatinib blocks tumor angiogenesis and cell proliferation by inhibiting signaling pathways such as vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), RET and KIT, thereby inhibiting tumor growth and metastasis. This "multi-channel blocking" mechanism enables lenvatinib to show good clinical therapeutic potential for a variety of tumor types, especially in the field of renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and endometrial cancer.

Currently, lenvatinib has been approved for marketing in many countries and regions, including China, the United States, Japan and the European Union, and has been included in the domestic medical insurance directory. It is often used in combination with immunotherapy drugs such as pembrolizumab (Pembrolizumab), and has shown higher objective response rates in the treatment of advanced liver cancer and endometrial cancer. Overseas studies have pointed out that lenvatinib can enhance the sensitivity of immunotherapy by inhibiting tumor vascular remodeling and regulating the tumor immune microenvironment, thereby improving patient survival benefits. This mechanism makes it gradually become one of the representative targeted drugs in various refractory cancers.

In terms of efficacy, the clinical application of lenvatinib in patients with differentiated thyroid cancer (DTC) has shown significant tumor shrinkage and disease control effects. It is often used as an alternative or combined drug with sorafenib in hepatocellular carcinoma. Overseas data show that some patients can achieve long-term disease stability. In kidney cancer treatment, lenvatinib can be used in combination with everolimus to improve treatment response rates. Its efficacy is not only reflected in inhibiting tumor growth, but also plays a positive role in improving patients' quality of life and prolonging progression-free survival.

However, as a potent multi-target TKI, lenvatinib also has complex side effects, which are mainly related to its inhibition of vascular and metabolic pathways. The most common clinical adverse reactions include hypertension, fatigue, decreased appetite, weight loss, diarrhea, and proteinuria. Among them, hypertension is considered to be one of the most representative side effects, because drugs that inhibit angiogenesis can cause an increase in vascular resistance. Some patients may develop hypothyroidism or abnormal liver function, so blood pressure, liver and kidney function, and thyroid hormone levels need to be measured regularly during treatment.

During long-term medication, some patients may develop hand-foot syndrome, stomatitis or gastrointestinal discomfort. Most of these reactions can be alleviated by adjusting the dose or stopping the medication for a short period of time. Doctors usually advise patients to start with a low dose and titrate as tolerated.

In general, lenvatinib is an anti-cancer targeted drug with precise efficacy and wide indications. Its application in a variety of malignant tumors continues to expand, especially in combination immunotherapy strategies, showing significant advantages. Although there are certain side effects, most patients can still tolerate it well through scientific monitoring and dose adjustment.

Reference materials:https://www.lenvima.com/